Life Science Innovation: Who Should Pay?
The panel discussion “Life Science Innovation: Who Should Pay?” was held May 9 at WBUR’s CitySpace. Hosted by Questrom’s Ravi K. Mehrotra Institute for Business, Markets, and Society, panelists Curt Nickisch (Questrom’13), Harvard Business Review IdeaCast cohost (from right), U.S. Rep. Jake Auchincloss (D-Mass.), Rena Conti, a Questrom associate professor of markets, public policy, and law, Michael Sherman, RA Capital Management venture partner, and Andrew Obenshain, biotech company bluebird bio CEO, explored how to ensure continued innovation and access to gene and cell therapy without breaking the bank. Photo by Melissa Ostrow
Comments & Discussion
Boston University moderates comments to facilitate an informed, substantive, civil conversation. Abusive, profane, self-promotional, misleading, incoherent or off-topic comments will be rejected. Moderators are staffed during regular business hours (EST) and can only accept comments written in English. Statistics or facts must include a citation or a link to the citation.